Robin Deterding, ERS 2022: Findings from the InPedILD Trial

The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study.

The abstract ‘Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial.‘ was presented at ERS 2022, 4–6 September, 2022.

Questions

1. What were the aims, design and eligibility criteria of the InPedILD trial? (0:35)
2. What were the primary and secondary efficacy and safety endpoints, and how well were they achieved? (2:41)
3. On the basis of these findings, what further studies are planned? (7:43)

Disclosures: Robin Deterding discloses consulting for Boehringer Ingelheim; receiving grant/ research support from Boehringer Ingelheim; and serving on advisory boards for Boehringer Ingelheim.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ERS meeting 2022.